Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer

Simple item page
dc.contributor.authorSezgin, C
dc.contributor.authorKarabulut, B
dc.contributor.authorUslu, R
dc.contributor.authorSanli, UA
dc.contributor.authorGoksel, G
dc.contributor.authorZekioglu, O
dc.contributor.authorOzdemir, N
dc.contributor.authorGoker, E
dc.date.accessioned2025-04-10T10:35:22Z
dc.date.available2025-04-10T10:35:22Z
dc.description.abstractThe authors compare results obtained from weekly paclitaxel treatment in advanced breast cancer patients with biological and clinical prognostic factors. Expression of c-erbB-2, Ki-67, p53 and hormone receptors (HR) was examined by immunohistochemistry in samples of breast tissue from 30 patients. Univariate analysis showed that Ki-67 positivity and low performance status (PS) were associated with poor outcome (P < 0.05). We observed that expression of p53 and c-erbB-2 did not have any negative effect on response to chemotherapy and survival. HR-negative patients had better response and slightly statistically significant overall survival (OS) rates compared to HR-positive patients (P > 0.05). In a multivariate analysis low PS was the only significant predictor of shorter survival (P < 0.05). In conclusion, while the expression of p53 and c-erbB-2 did not have any effect on treatment results, negative Ki-67 expression and negative HR status were associated with better OS in this patient population. PS was the only significant predictor for OS.
dc.identifier.e-issn1973-9478
dc.identifier.issn1120-009X
dc.identifier.urihttp://hdl.handle.net/20.500.14701/41409
dc.language.isoEnglish
dc.titlePotential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu